Home / Stocks / Suven Life Sciences Ltd
SUVEN

Suven Life Sciences Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹276.9

Change

+11.25 (4.23%)

Open

₹264.5

Prev. Close

₹265.65

Day High

₹279.0

Day Low

₹260.5

Volume Analysis

Traded

368,055

Delivered

159,821

Delivery %

43.42%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (4)

  • •Low return on equity (-81.5%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (34/100)
  • •Low operating margin (-4367.0%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹302.26 ₹290.63 ₹283.76 ₹272.13 ₹265.26 ₹253.63 ₹246.76
Fibonacci ₹290.63 ₹283.56 ₹279.2 ₹272.13 ₹265.06 ₹260.7 ₹253.63
Camarilla ₹281.99 ₹280.29 ₹278.6 ₹272.13 ₹275.2 ₹273.51 ₹271.81

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+68.13%

1 Week

-1.69%

1 Month

-0.63%

3 Months

-25.79%

6 Months

+4.31%

1 Year

+56.37%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-47.54%

Net margin -4244.44% × asset turnover 0.01x × equity multiplier 1.12x

Company Overview

Sector

Healthcare

Market Cap

₹7,850 Cr

ROE

-81.5%

Book Value

₹16.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Suven Life Sciences Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 34/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-81.5%); promoter holding is falling.

TopFund Score — Fundamentals Quality

34/100 — Weak

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

0

Valuation

0

Cash Flow

6

Corporate Governance

43

Momentum

55

Institutional Ownership

42

Business Quality

20

Risk & Volatility

44

Liquidity

47

From Screener.in

  • +Company is almost debt free.
  • −Stock is trading at 17.3 times its book value
  • −Company has low interest coverage ratio.
  • −Promoter holding has decreased over last quarter: -4.61%
  • −The company has delivered a poor sales growth of -12.0% over past five years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Suven Life Sciences will present seven CNS pipeline posters at Neuroscience 2026 in Washington DC, November 14–18.

Crisil report for Q2 FY27 notes 10% deviation approved, with Rs 53,763.36 lakh utilized under preferential issue.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 3 2 2 1 3 2 1 2 1 3 2 4 1
Expenses + 27 49 33 32 55 41 45 53 81 106 52 136 112
Operating Profit -24 -46 -30 -31 -52 -39 -44 -51 -80 -103 -51 -132 -111
OPM % -768.0% -1,885.0% -1,267.0% -3,024.0% -2,032.0% -2,435.0% -2,981.0% -2,714.0% -8,671.0% -3,678.0% -3,331.0% -3,711.0% -9,242.0%
Other Income + 13 6 4 4 4 2 1 1 4 3 7 8 7
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 2 2 2 1 1 2 1 1 1 1 2 2 2
Profit before tax -13 -42 -28 -28 -50 -39 -44 -52 -77 -102 -46 -128 -107
Tax % 0.0% 0.0% -4.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Profit + -13 -42 -27 -28 -50 -39 -44 -52 -77 -102 -46 -128 -107
EPS in Rs -1 -2 -1 -1 -2 -2 -2 -2 -3 -4 -2 -5 -4
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -30 -18 -8 -73 -16 -34 -38 85 -64 75 3 91 30

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 521 499 543 625 286 13 13 12 14 12 7 7 9
Expenses + 361 398 414 427 300 128 93 134 139 140 172 291 406
Operating Profit 159 102 129 198 -14 -116 -80 -122 -126 -128 -166 -284 -397
OPM % 31.0% 20.0% 24.0% 32.0% -5.0% -917.0% -593.0% -1,032.0% -929.0% -1,094.0% -2,487.0% -3,999.0% -4,367.0%
Other Income + 9 19 21 23 27 14 8 5 14 29 11 14 24
Interest 5 6 6 5 2 1 1 1 0 0 0 0 1
Depreciation 12 18 21 21 11 4 4 4 7 6 6 6 7
Profit before tax 152 98 123 196 0 -106 -77 -122 -118 -106 -161 -276 -382
Tax % 28.0% 26.0% 29.0% 37.0% 15,038.0% -11.0% -7.0% 0.0% 0.0% -1.0% 0.0% 0.0% —
Net Profit + 109 72 87 124 -24 -94 -72 -122 -118 -105 -161 -276 -382
EPS in Rs 8 5 6 9 -2 -7 -5 -8 -5 -5 -7 -10 -15
Dividend Payout % 7.0% 35.0% 15.0% 15.0% -80.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — -4 9 15 -54 -96 7 -12 14 -14 -43 7 55

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 547 583 654 755 226 131 95 82 354 248 88 565 425
Borrowings + 109 83 71 34 3 6 5 3 2 1 0 17 16
Other Liabilities + 105 74 78 118 62 33 16 9 12 14 25 16 37
Total Liabilities 773 751 816 919 303 182 128 108 389 285 135 624 506
Fixed Assets + 172 305 306 308 22 25 21 38 37 28 60 73 115
CWIP 107 7 10 25 0 0 5 4 0 0 0 4 4
Investments 0 0 301 279 223 0 0 45 46 76 22 181 14
Other Assets + 494 439 199 308 58 157 103 22 305 181 53 367 374
Total Assets 773 751 816 919 303 182 128 108 389 285 135 624 506
Equity Capital 13 13 13 13 13 13 13 15 22 22 22 26 28

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 143 68 109 70 -53 -135 -96 -128 -116 -115 -155 -300
Cash from Investing Activity + -110 -39 -311 -1 30 146 56 -22 -248 94 155 -462
Cash from Financing Activity + 179 -68 -30 -52 5 3 35 146 396 -1 -1 757
Net Cash Flow 212 -39 -232 17 -18 14 -5 -4 32 -22 -1 -5
Free Cash Flow 25 10 79 28 -92 -137 -102 -147 -119 -113 -193 -305
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 113 93 111 57 262 114 119 104 91 95 93 106

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 69.56% → 65.47%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 29.88% 28.91% 28.21% 28.34% 28.35% 29.47% 29.12% 28.07% 28.18% 24.32% 26.42% 31.89%
Promoters 69.56% 69.56% 70.26% 70.26% 70.26% 70.26% 70.26% 67.36% 67.36% 70.15% 70.08% 65.47%
FII 0.54% 0.46% 0.45% 0.33% 0.34% 0.25% 0.58% 1.17% 1.07% 0.91% 0.56% 0.45%
DII 0.01% 1.05% 1.05% 1.05% 1.05% 0.01% 0.03% 3.39% 3.39% 4.62% 2.93% 2.17%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Suven Life Sciences Ltd (this stock) 7,850 — 17.38 -81.5%
Thyrocare Tech Ltd 7,940 45.3 14.31 28.4%
Sanofi India Limited 7,603 17.2 8.83 47.1%
Healthcare Glob. Ent. Ltd 8,562 216.0 6.36 2.54%
Kovai Medical Center & Ho 7,108 123.0 24.58 22.2%
Bliss Gvs Pharma Ltd 7,075 43.5 5.5 11.8%
Sun Pharma Adv.res.co.ltd 6,680 4.05 4.64 279.0%

Which Mutual Funds Hold Suven Life Sciences Ltd?

Frequently Asked Questions about Suven Life Sciences Ltd

Community Sentiment

What are other investors saying about Suven Life Sciences Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.